Your browser doesn't support javascript.
loading
Cytotoxicity evaluation using cryopreserved primary human hepatocytes in various culture formats.
Richert, Lysiane; Baze, Audrey; Parmentier, Céline; Gerets, Helga H J; Sison-Young, Rowena; Dorau, Martina; Lovatt, Cerys; Czich, Andreas; Goldring, Christopher; Park, B Kevin; Juhila, Satu; Foster, Alison J; Williams, Dominic P.
Afiliação
  • Richert L; KaLy-Cell, 20A rue du Général Leclerc, 67115 Plobsheim, France; Université de Franche-Comté, EA 4267 Besançon, France. Electronic address: l.richert@kaly-cell.com.
  • Baze A; KaLy-Cell, 20A rue du Général Leclerc, 67115 Plobsheim, France. Electronic address: a.baze@kaly-cell.com.
  • Parmentier C; KaLy-Cell, 20A rue du Général Leclerc, 67115 Plobsheim, France. Electronic address: c.parmentier@kaly-cell.com.
  • Gerets HHJ; UCB BioPharma SPRL, Non-Clinical Development, Chemin du Foriest, 1420 Braine-l'Alleud, Belgium. Electronic address: helga.gerets@ucb.com.
  • Sison-Young R; MRC Centre for Drug Safety Science, Department of Molecular and Clinical Pharmacology, Sherrington Building, Ashton Street, University of Liverpool, Liverpool L69 3GE, UK. Electronic address: Rowena.Sison-Young@liverpool.ac.uk.
  • Dorau M; Sanofi-Aventis Deutschland GmbH, R&D DSAR Preclinical Safety, Industriepark Hoechst, D-65926 Frankfurt, Germany. Electronic address: Martina.Dorau@sanofi.com.
  • Lovatt C; GlaxoSmithKline, Safety Assessment, Stevenage, Hertfordshire, UK. Electronic address: cerys.a.lovatt@gsk.com.
  • Czich A; Sanofi-Aventis Deutschland GmbH, R&D DSAR Preclinical Safety, Industriepark Hoechst, D-65926 Frankfurt, Germany. Electronic address: Andreas.Czich@sanofi.com.
  • Goldring C; MRC Centre for Drug Safety Science, Department of Molecular and Clinical Pharmacology, Sherrington Building, Ashton Street, University of Liverpool, Liverpool L69 3GE, UK. Electronic address: C.E.P.Goldring@liverpool.ac.uk.
  • Park BK; MRC Centre for Drug Safety Science, Department of Molecular and Clinical Pharmacology, Sherrington Building, Ashton Street, University of Liverpool, Liverpool L69 3GE, UK. Electronic address: B.K.Park@liv.ac.uk.
  • Juhila S; Orion Corporation, R&D, In Vitro Biology, Orionintie 1A, P.O. Box 65, FI-02101 Espoo, Finland. Electronic address: satu.juhila@orionpharma.com.
  • Foster AJ; Translational Safety, Drug Safety & Metabolism, AstraZeneca, Cambridge Science Park, Cambridge, UK. Electronic address: Alison.Foster2@astrazeneca.com.
  • Williams DP; Translational Safety, Drug Safety & Metabolism, AstraZeneca, Cambridge Science Park, Cambridge, UK. Electronic address: Dominic.P.Williams@astrazeneca.com.
Toxicol Lett ; 258: 207-215, 2016 Sep 06.
Article em En | MEDLINE | ID: mdl-27363785
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Criopreservação / Drogas em Investigação / Hepatócitos / Avaliação Pré-Clínica de Medicamentos / Microambiente Celular Tipo de estudo: Etiology_studies / Prognostic_studies Limite: Animals / Humans Idioma: En Revista: Toxicol Lett Ano de publicação: 2016 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Criopreservação / Drogas em Investigação / Hepatócitos / Avaliação Pré-Clínica de Medicamentos / Microambiente Celular Tipo de estudo: Etiology_studies / Prognostic_studies Limite: Animals / Humans Idioma: En Revista: Toxicol Lett Ano de publicação: 2016 Tipo de documento: Article